PriceTargets.com logo

Monte Rosa Therapeutics - GLUE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.00
  • Forecasted Upside: 90.48%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$8.40 As of 11/21/2024 11:25 AM ET
▲ +0.04 (0.48%)

This chart shows the closing price for GLUE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Monte Rosa Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GLUE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLUE

Analyst Price Target is $16.00
▲ +90.48% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Monte Rosa Therapeutics in the last 3 months. The average price target is $16.00, with a high forecast of $17.00 and a low forecast of $15.00. The average price target represents a 90.48% upside from the last price of $8.40.

This chart shows the closing price for GLUE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Monte Rosa Therapeutics. This rating has held steady since July 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/7/2024WedbushReiterated RatingOutperform$15.00
9/12/2024WedbushReiterated RatingOutperform ➝ Outperform$11.00 ➝ $11.00
8/12/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$18.00 ➝ $17.00
6/28/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$16.00 ➝ $16.00
5/22/2024WedbushReiterated RatingOutperform ➝ Outperform$11.00
2/15/2024WedbushInitiated CoverageOutperform$11.00
10/19/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$31.00 ➝ $11.00
8/11/2023Credit Suisse GroupReiterated RatingNeutral ➝ Neutral$11.00
3/17/2023Credit Suisse GroupLower TargetNeutral$12.00 ➝ $11.00
1/2/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$18.00
11/16/2022Credit Suisse GroupLower Target$12.00
10/13/2022UBS GroupInitiated CoverageBuy$22.00
8/15/2022Jefferies Financial GroupInitiated CoverageBuy$20.00
5/11/2022Piper SandlerLower Target$40.00 ➝ $21.00
4/28/2022Credit Suisse GroupInitiated CoverageNeutral$19.00
2/10/2022Wells Fargo & CompanyInitiated CoverageEqual Weight$19.00
1/3/2022GuggenheimLower Target$40.00 ➝ $35.00
11/17/2021Berenberg BankInitiated CoverageBuy
10/14/2021Leerink PartnersInitiated CoverageMarket Perform$20.00
7/19/2021JPMorgan Chase & Co.Initiated CoverageOverweight$38.00
7/19/2021GuggenheimInitiated CoverageBuy$30.00
7/19/2021Piper SandlerInitiated CoverageOverweight$40.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 7 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 7 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Monte Rosa Therapeutics logo
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $8.40
Low: $8.20
High: $8.48

50 Day Range

MA: $6.66
Low: $4.80
High: $10.01

52 Week Range

Now: $8.40
Low: $2.91
High: $12.40

Volume

61,182 shs

Average Volume

757,412 shs

Market Capitalization

$516.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Monte Rosa Therapeutics?

The following Wall Street analysts have issued research reports on Monte Rosa Therapeutics in the last year: Piper Sandler, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for GLUE.

What is the current price target for Monte Rosa Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Monte Rosa Therapeutics in the last year. Their average twelve-month price target is $16.00, suggesting a possible upside of 91.4%. Wells Fargo & Company has the highest price target set, predicting GLUE will reach $17.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $15.00 for Monte Rosa Therapeutics in the next year.
View the latest price targets for GLUE.

What is the current consensus analyst rating for Monte Rosa Therapeutics?

Monte Rosa Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GLUE will outperform the market and that investors should add to their positions of Monte Rosa Therapeutics.
View the latest ratings for GLUE.

What other companies compete with Monte Rosa Therapeutics?

Other companies that are similar to Monte Rosa Therapeutics include C4 Therapeutics, Icosavax, Kinnate Biopharma, Seres Therapeutics and Invivyd. Learn More about companies similar to Monte Rosa Therapeutics.

How do I contact Monte Rosa Therapeutics' investor relations team?

The company's listed phone number is 617-949-2643 and its investor relations email address is [email protected]. The official website for Monte Rosa Therapeutics is www.monterosatx.com. Learn More about contacing Monte Rosa Therapeutics investor relations.